Your browser doesn't support javascript.
loading
The role of CSTF2 in cancer: from technology to clinical application.
Ding, Jiaxiang; Su, Yue; Liu, Youru; Xu, Yuanyuan; Yang, Dashuai; Wang, Xuefeng; Hao, Shuli; Zhou, Huan; Li, Hongtao.
Afiliação
  • Ding J; Clinical Trial Center of the First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
  • Su Y; School of Public Foundation, Bengbu Medical University, Bengbu, Anhui, China.
  • Liu Y; Clinical Trial Center of the First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
  • Xu Y; School of Public Foundation, Bengbu Medical University, Bengbu, Anhui, China.
  • Yang D; The People's Hospital of Bozhou, Bozhou, Anhui, China.
  • Wang X; Clinical Trial Center of the First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
  • Hao S; School of Pharmacy, Bengbu Medical University, Bengbu, Anhui, China.
  • Zhou H; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province; School of Pharmacy, Anhui Medical University, Hefei, Anhui, China.
  • Li H; Clinical Trial Center of the First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Cell Cycle ; 22(23-24): 2622-2636, 2023.
Article em En | MEDLINE | ID: mdl-38166492
ABSTRACT
A protein called cleavage-stimulating factor subunit 2 (CSTF2, additionally called CSTF-64) binds RNA and is needed for the cleavage and polyadenylation of mRNA. CSTF2 is an important component subunit of the cleavage stimulating factor (CSTF), which is located on the X chromosome and encodes 557 amino acids. There is compelling evidence linking elevated CSTF2 expression to the pathological advancement of cancer and on its impact on the clinical aspects of the disease. The progression of cancers, including hepatocellular carcinoma, melanoma, prostate cancer, breast cancer, and pancreatic cancer, is correlated with the upregulation of CSTF2 expression. This review provides a fresh perspective on the investigation of the associations between CSTF2 and various malignancies and highlights current studies on the regulation of CSTF2. In particular, the mechanism of action and potential clinical applications of CSTF2 in cancer suggest that CSTF2 can serve as a new biomarker and individualized treatment target for a variety of cancer types.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fator Estimulador de Clivagem / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fator Estimulador de Clivagem / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article